// App-Quantinova.ai

2961 : deBouganin conjugated to trastuzumab overcomes multiple mechanisms of T-DM1 drug resistance

Researchers

Presenter

  • Rachelle L. Dillon

Principal Investigators

  • Shilpa Chooniedass

  • Arjune Premsukh

  • Gregory P. Adams

  • Joycelyn Entwistle

  • Glen C. MacDonald

  • Jeannick Cizeau

Medical Centers

  • Viventia Bio Inc., Winnipeg, Manitoba, Canada

  • Viventia Bio Inc, Philadelphia, PA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

  • Nucleoside diphosphate kinase A

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • ricin

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved